Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from agalsidase alfa to agalsidase beta in Fabry disease with gastrointestinal involvement
2018-000368-27Phase 4Completed
- Sponsor
- Policlinico Gemelli
- Start
- Nov 2020
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of agalsidase beta in Fabry disease (FD), sponsored by Policlinico Gemelli. Primary endpoints: Change in plasma lyso-GL3 levels after switch to agalsidase beta and Change in gastrointestinal symptoms after switch to agalsidase beta. Started Nov 2020; status: completed.
02
Drugs
agalsidase beta
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2018-000368-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000368-27.